Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

BACKGROUND: In the randomised Phase 3 IMpassion130 trial, atezolizumab combined with nab-paclitaxel (atezo + nab-P) in 902 patients with triple-negative breast cancer (TNBC) showed prolonged progression-free survival (PFS) in both the intention-to-treat (ITT) population and programmed death-ligand 1...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Jpn J Clin Oncol
Main Authors: Iwata, Hiroji, Inoue, Kenichi, Kaneko, Koji, Ito, Yoshinori, Tsugawa, Koichiro, Hasegawa, Ayumi, Nakagawa, Shintaro, Kuratomi, Hiroyasu, Tamura, Kenji
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2019
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935297/
https://ncbi.nlm.nih.gov/pubmed/31612909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyz135
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker